Using our Arestat™ technology platform, we are developing enhanced medicines for diabetes and other indications through our proprietary pipeline and in partnership with leading pharmaceutical and biotechnology companies

Our Products

Our potential products for diabetes and for specialist hospital use are designed to improve patient outcomes and enable healthier lives

Our Partners

We work with many of the top 20 leading pharmaceutical companies to enhance product formats, find solutions to development challenges and create differentiated products offering the potential for significant improvements in patient safety and convenience

Latest News and Events

  • 16th June 2022

    ARECOR ANNOUNCES EXCLUSIVE COLLABORATION WITH A TOP 5 GLOBAL PHARMACEUTICAL COMPANY

  • 18th May 2022

    ARECOR TO HOST KOL WEBINAR ON THE NEED FOR CONCENTRATED AND RAPID ACTING INSULIN TREATMENTS IN DIABETES CARE

  • 28th April 2022

    ARECOR PRESENTS FULL DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES AT ATTD MEETING